Milan J. Anadkat
Barnes-Jewish Hospital(US)University of Washington(US)Washington University in St. Louis(US)Clinical Trial Investigators(US)
Publications by Year
Research Areas
Chemotherapy-related skin toxicity, Psoriasis: Treatment and Pathogenesis, Colorectal Cancer Treatments and Studies, Autoimmune Bullous Skin Diseases, Dermatology and Skin Diseases
Most-Cited Works
- → Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities(2011)428 cited
- → First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation(2018)401 cited
- → Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0(2012)351 cited
- → Trial of Spesolimab for Generalized Pustular Psoriasis(2021)323 cited
- → NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer(2009)136 cited
- → Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial(2023)